Press Releases



    • NOV 20 2019

    ONC201 and ONC206 Activity in Neuro-Oncology to be Presented at SNO Conference

    Philadelphia, PA (November 20, 2019) – Oncoceutics, Inc. announced that new data will be presented on the efficacy and mechanism of action of imipridones ONC201 and ONC206 at the 24nd Annual Scientific Meeting of the Society of Neuro-Oncology, to be held November 20th-24th in Phoenix, Arizona. These data will highlight exciting findings that have emerged

    • NOV 19 2019

    Publication in Nature Communications Confirms DRD2 as Target of ONC201

    Philadelphia, PA (Nov. 19, 2019) – Oncoceutics, Inc. announced a publication in the journal Nature Communications demonstrating selective antagonism of the G-protein coupled receptor (GPCR) dopamine receptor D2 (DRD2) by Oncoceutics’ lead candidate imipridone, ONC201. ONC201 was found to specifically bind and antagonize DRD2, and its functionally redundant family member DRD3, without affecting other dopamine

    • NOV 13 2019

    Clinical Efficacy of Weekly ONC201 in Adult Recurrent Glioblastoma Published

    Philadelphia, PA (November 13, 2019) – Oncoceutics, Inc. announced that results from the second and third cohort of the Phase II trial for patients with recurrent glioblastoma treated with the company’s lead imipridone, ONC201, were recently published in the journal Neuro-Oncology. This manuscript represents the third publication among a series of reports demonstrating durable radiographic

    • SEP 16 2019

    Oncoceutics Commemorates National Childhood Cancer Awareness Month

    Philadelphia, PA (September 16, 2019) – Oncoceutics, a clinical-stage drug discovery and development company, commemorates National Childhood Cancer Awareness Month this September and reiterates its support for children and all those affected by childhood cancer. Cancer remains one of the greatest current health challenges, and childhood cancer kills more children in the United States than